The US Food and Drug Administration has given the green light to US marketing of a noninvasive medical device developed by Jerusalem-based Brainsway Ltd. to treat obsessive-compulsive disorder.
OCD is a common, chronic disorder in which the sufferer has uncontrollable, recurring thoughts and feels compelled to repeat certain behaviors over and over. It is typically treated with medication, psychotherapy or a combination of the two. According to the National Institute of Mental Health, about 1 percent of US adults had OCD in the past year. Although most patients respond to treatment, some continue to experience symptoms, the FDA said in a statement announcing its decision on August 17.
“No serious adverse reactions related to the Brainsway device were reported,” said the FDA in its statement.
In a filing to the Tel Aviv Stock Exchange on Sunday, Brainsway said that at the moment, Brainsway is the only company to receive FDA approval for a device to treat OCD using the TMS system.
Please contact us to find out more and see how you may be able to add an investment like this or basket to your portfolio: email@example.com